Company Overview of Knopp Biosciences LLC
Knopp Biosciences LLC engages in the discovery and development of drugs for the treatments of neurological disorders. It offers KNS-760704, a drug candidate for the treatment of amyotrophic lateral sclerosis. Knopp Biosciences LLC was founded in 2010 and is based in Pittsburgh, Pennsylvania.
2100 Wharton Street
Pittsburgh, PA 15203
Founded in 2010
Key Executives for Knopp Biosciences LLC
Chief Executive Officer, President and Member of The Board of Directors
Evp, Corporate Operations & Finance and Member of The Board of Directors
Chief Operating Officer and Senior Vice President of Clinical Research & Business Operations
Head of Clinical and Translational Medicine
Evp, Business Development & Public Affairs and Member of The Board of Directors
Compensation as of Fiscal Year 2015.
Knopp Biosciences LLC Key Developments
Calman Prussin Joins Knopp Biosciences to Lead Clinical Development of Dexpramipexole in Eosinophilic Asthma
Jan 7 16
Knopp Biosciences LLC announced that Calman Prussin, M.D. has joined Knopp to head clinical and translational medicine in immunology. In this capacity, Dr. Prussin will lead clinical development of dexpramipexole in asthma and other allergic diseases characterized by elevated eosinophils, which are white bloods cells associated with inflammation. Dexpramipexole is an oral small molecule demonstrated in ongoing clinical trials to lower levels of eosinophils in blood and inflamed tissues. Dr. Prussin comes to Knopp from the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH). He has acted as principal investigator in numerous clinical trials in eosinophil-associated diseases, served on the Pulmonary-Allergy Drugs Advisory Committee of the Food and Drug Administration, and is the author of 100 peer-reviewed research papers, review articles, book chapters, and abstracts. He remains a director of the American Board of Allergy and Immunology.
Knopp Biosciences LLC Collaborate with National Institute of Allergy and Infectious Diseases to Investigate on Hypereosinophilic Syndrome Studies
Mar 20 14
Knopp Biosciences LLC has announced a second collaboration with the National Institute of Allergy and Infectious Diseases, (NIAID), to investigate the eosinophil-lowering effects of the investigational drug dexpramipexole. Execution of the latest Cooperative R&D Agreement (CRADA) between Knopp and NIAID follows an agreement announced in January under which NIAID will sponsor a Phase II proof-of-concept clinical trial of dexpramipexole in hypereosinophilic syndrome (HES). Taken together, the agreements span the preclinical and clinical evaluation of dexpramipexole as a potential treatment for diseases characterized by elevated eosinophils, a type of white blood cell. Multiple clinical studies have shown that dexpramipexole reduces blood eosinophils in patients with amyotrophic lateral sclerosis (ALS). In addition, a reduction of blood eosinophils has been demonstrated in preclinical studies of dexpramipexole. These results are the basis for the hypothesis that dexpramipexole may be a potential treatment for diseases characterized by elevated eosinophils, for which off-label corticosteroid administration generally remains first-line treatment. The principal goals of the latest CRADA are to further elucidate the mechanistic effects of dexpramipexole administration in hypereosinophilic mice in vivo and to evaluate the drug's interactions with eosinophil progenitors in tissue culture. The manner in which dexpramipexole reduces eosinophil counts in animals may help guide translational studies in eosinophil-related human disease.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries